Article

ASCO Supports Act to Reduce Co-Pays for Specialty Medications

Author(s):

The Patients' Access to Treatments Act of 2015 was introduced earlier this year to rein in the high cost-sharing requirements for specialty drugs.

Earlier this year, US Representatives David McKinley (R-WV) and Lois Capps (D-CA), co-sponsored the Patients' Access to Treatments Act of 2015 that is applicable to health plans that have formulariers or a tiered cost-sharing structure. The objective: reduce the increasing cost-sharing requirements for patients imposed by the preferred versus non-preferred tiering of some of the prescription medications.

The American Society of Clinical Oncology has now announced that it endorses the Act that will shield patients from mounting co-payment burdens of specialty formulations.

“The imposition of high cost-sharing requirements is increasingly becoming a barrier for cancer patients,” wrote ASCO President Julie Vose, MD, MBA, FASCO. “In some cases, cancer patients are simply unable to afford the appropriate treatment, placing them at risk of a less successful outcome, or a more debilitating treatment regimen.”

Related Videos
Screenshot of an interview with Ruben Mesa, MD
dr carol regueiro
dr carol regueiro
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
dr carol regueiro
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo